Relapse pattern and treatment outcome of curative radiotherapy for primary cutaneous CD30+ anaplastic large-cell lymphoma: A retrospective cohort study

Primary cutaneous anaplastic large-cell lymphoma (PCALCL), a unique category of mature T-cell neoplasms, was recognized in the 2008 WHO classification of lymphoid tumour as an indolent primary cutaneous CD30+ lymphoproliferative disorder (1). Radiotherapy (RT), which is frequently used for curative treatment of patients with PCALCL, involves only a few lesions or may be used to palliate the disorder in patients with multiple lesions. However, because of the rarity of PCALCL and the low number of cohort series and case reports investigating the disorder, the outcomes of using curative RT alone for CD30+ PCALCL are underreported, published studies have revealed that rapid recurrence of CD30+ PCALCL occurs within 2-8 months after treatment (2-4). ? 2016 The Authors.